
Nuvera Biosciences Inc (AKA: Silico Insights Inc) Profile last edited on: 6/15/2021
CAGE: 3KYE9
UEI:
Business Identifier: Molecular diagnostics for oncology diseases Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
400 West Cummings Park Suite 5350
Woburn, MA 01801
Woburn, MA 01801
(781) 938-3844 |
info@nuverabio.com |
www.nuverabio.com |
Location: Single
Congr. District: 05
County: Middlesex
Congr. District: 05
County: Middlesex
Public Profile
Unitl 2005 dba Silico Insights, Inc, Nuvera Biosciences, Inc., a molecular diagnostics company, developing diagnostic solutions for oncology diseases. Launched out of University of Texas M. D. Anderson Cancer Center based on pioneering multi-gene profiling in cancer treatment trials, the company focuses on developing breast cancer genomic assays. Products include aromatase inhibitors, anthracycline-based chemotherapy, and biomarkers for breast cancer patients. Nuvera Biosciences has developed a novel, proprietary research and computational platform that enables a complete understanding of data dependencies and inter-relationships. The technology platform has the capability to study and connect disparate physiological and clinical events and establish key, quantitative dependencies across the entire drug discovery and development pipeline. In drug discovery, validation of key pathway elements using tissue-based approaches delivers new avenues for diagnostic products and screening tests for drug candidates. The Company has also built a unique portfolio within cancer and inflammation-based diseases through its collaborations and projects that consists of methodologies for marker characterization and validation. Some of these ongoing developments are now focused on potential commercialization of these markers as diagnostic and drug tests in specific cancer areas
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2007 | 1 | NIH | $98,393 | |
Project Title: Development and validation of predictors of endocrine treatment sensitivity | ||||
2007 | 1 | NIH | $96,554 | |
Project Title: Cancer markers from bimodally expressed genes | ||||
2006 | 2 | Army | $849,886 | |
Project Title: A Metabolomic Framework in Predicting Optimal Fitness and Performance | ||||
2005 | 1 | AF | $99,825 | |
Project Title: Developing Bioinformatics Tools for Proteomics Research | ||||
2005 | 2 | OSD | $829,530 | |
Project Title: Data Mining Infrastructure to Characterize Medically Unexplained Symptoms |
Key People / Management
Nandan Padukone -- Chief Executive Officer, President and Director
Christos Hatzis
Christos Hatzis
Company News
There are no news available.